Nimustine use in the treatment of feline lymphoma

Nimustine was well tolerated and showed clinical outcomes similar to lomustine in cats with lymphoma

Nimustine, similar to lomustine, is an alkylating agent from the nitrosourea family. There have been some reports regarding lomustine treatment for tumour-bearing cats. However, information regarding nimustine treatment for tumour-bearing cats is limited.

To retrospectively evaluate adverse events and clinical outcomes in tumour-bearing cats receiving nimustine.

Information regarding diagnosis, treatment condition, adverse events, and clinical outcomes was collected in tumour-bearing cats receiving nimustine through reviews of medical records.

Nine cats with lymphoma were treated with nimustine in the primary therapy (n = 2) and in the rescue therapy (n = 7). The median starting dose of nimustine was 25 mg/m2 (range: 20-30 mg/m2) with dosing interval of three weeks and 1-11 administrations. Adverse events were mild gastrointestinal toxicity (grade 1) including diarrhoea (n = 2) and vomiting (n = 2) and mild myelosuppression (grade 1 or 2) including thrombocytopenia (n = 3) and neutropenia (n = 1). No severe adverse events were observed. Progression-free survival durations among cats receiving nimustine in the primary therapy and in the rescue therapy were 274-688 days (median: 481 days) and 9-671 days (median: 102 days), respectively. Overall survival duration among cats receiving nimustine in the primary therapy and in the rescue therapy were 275-745 days (median: 510 days) and 14-671 days (median: 109 days), respectively.

Nimustine was well tolerated and showed clinical outcomes similar to lomustine in cats with lymphoma. These findings suggest that nimustine might be an alternative to lomustine in the treatment of feline lymphoma.

“Retrospective evaluation of nimustine use in the treatment of feline lymphoma”. Kosei Sakai, et al. Vet Med Sci. 2021 Oct 2. doi: 10.1002/vms3.652.

Like0

Dislike0

List
Add

Please enter a comment

Name *

Email address *

Comment *

* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.

I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies

Tag

Like0

Dislike0

EVENTS

Edrapublishing

About Us Authors Contact Us Legal Notes Privacy Search

Top

Nimustine use in the treatment of feline lymphoma

Nimustine was well tolerated and showed clinical outcomes similar to lomustine in cats with lymphoma

Comments

List

Add

Tag

More news

One Committed and Caring NC State Veterinary Student, So Many Choices

Dentalis Earns 5 VOHC® Seals, Positioning for Global Expansion in Animal Health

Advancing the 3Rs: innovation, implementation, ethics and society

Automated Knowledge-Based Radiation Treatment Planning in Canine and Feline Nasal Tumors

Does Lung Function Imaging Modality Have a Dosimetric Impact On Functional Avoidance Treatment Planning: Assessment Using Prospective Clinical Trial Data

Newsletter

News of interest

Advancing the 3Rs: innovation, implementation, ethics and society

Automated Knowledge-Based Radiation Treatment Planning in Canine and Feline Nasal Tumors

One Committed and Caring NC State Veterinary Student, So Many Choices

Philanthropic Support and Specialized Surgery Saves Dog with Oral Tumor

EVENTS